These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 34960246)

  • 1. Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months.
    Nomura Y; Sawahata M; Nakamura Y; Koike R; Katsube O; Hagiwara K; Niho S; Masuda N; Tanaka T; Sugiyama K
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine.
    Nomura Y; Sawahata M; Nakamura Y; Kurihara M; Koike R; Katsube O; Hagiwara K; Niho S; Masuda N; Tanaka T; Sugiyama K
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination.
    Koike R; Sawahata M; Nakamura Y; Nomura Y; Katsube O; Hagiwara K; Niho S; Masuda N; Tanaka T; Sugiyama K
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody level dynamics until after the third dose of COVID-19 vaccination.
    Asahi N; Sakamaki I; Hida Y; Torii K; Hashimoto N; Iwasaki H; Iwano M; Kimura H
    Heliyon; 2023 Jun; 9(7):e17477. PubMed ID: 37361132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.
    Kageyama T; Ikeda K; Tanaka S; Taniguchi T; Igari H; Onouchi Y; Kaneda A; Matsushita K; Hanaoka H; Nakada TA; Ohtori S; Yoshino I; Matsubara H; Nakayama T; Yokote K; Nakajima H
    Clin Microbiol Infect; 2021 Dec; 27(12):1861.e1-1861.e5. PubMed ID: 34375755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
    Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].
    Rojkovich B; Németh D; Török E; Szabó B; Pintér Á; Juhász I; Weidl M; Lányi É; Pável-Szecskó J; Lázár I; Perduk A; Reiter J; Nagy G; Nagy E; Géher P
    Orv Hetil; 2021 Sep; 162(39):1551-1557. PubMed ID: 34570721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2.
    Salvaggio M; Fusina F; Albani F; Salvaggio M; Beschi R; Ferrari E; Costa A; Agnoletti L; Facchi E; Natalini G
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine.
    Ragone C; Meola S; Fiorillo PC; Penta R; Auriemma L; Tornesello ML; Miscio L; Cavalcanti E; Botti G; Buonaguro FM; Bianchi A; Buonaguro L; Tagliamonte M
    Front Immunol; 2021; 12():734689. PubMed ID: 34386018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response (IgG) following full inoculation with BNT162b2 COVID‑19 mRNA among healthcare professionals.
    Tsatsakis A; Vakonaki E; Tzatzarakis M; Flamourakis M; Nikolouzakis TK; Poulas K; Papazoglou G; Hatzidaki E; Papanikolaou NC; Drakoulis N; Iliaki E; Goulielmos GN; Kallionakis M; Lazopoulos G; Kteniadakis S; Alegkakis A; Farsalinos K; Spandidos DA
    Int J Mol Med; 2021 Nov; 48(5):. PubMed ID: 34515322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
    Salmerón Ríos S; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Señalada JJB; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Murillo Romero A; Lauschke VM; Stebbing J; Abizanda P
    J Am Geriatr Soc; 2021 Jun; 69(6):1441-1447. PubMed ID: 33768521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose.
    Vicenti I; Basso M; Gatti F; Scaggiante R; Boccuto A; Zago D; Modolo E; Dragoni F; Parisi SG; Zazzi M
    Int J Infect Dis; 2021 Nov; 112():40-44. PubMed ID: 34481967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
    Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.